Most Read Articles
2 days ago
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
Tristan Manalac, 6 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
Pearl Toh, 3 days ago
Patients with inflammatory bowel disease (IBD) who had primary nonresponse to an anti-tumour necrosis factor (TNF) agent ─ or inadequate response to the initial loading doses ─ were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.
Tristan Manalac, 16 Feb 2018
Placebo pills, even when administered open-label, appear to significantly improve cancer-related fatigue and fatigue-disrupted quality of life, according to a recent study.

Using sex steroids may increase lumbar spine BMD in male-to-female transgenders

04 Dec 2017
Doctors and therapists are said to be failing transgender patients due to their lack of knowledge and expertise in the area.

The use of masculinizing hormone therapy in female-to-male (FTM) transgenders is not likely to lead to significant changes in bone mineral density (BMD), but in male-to-female (MTF) individuals, the use of feminizing hormone therapy may result in an increase in BMD at the lumbar spine, a recent study has found.

“The impact of these BMD changes on patient-important outcomes such as fracture risk is uncertain,” according to researchers.

Several databases were comprehensively searched through 7 April 2015 for studies assessing bone health in transgender individuals receiving sex steroids. Studies were selected and appraised by pairs of reviewers. Finally, researchers pooled weighted mean differences and 95 percent confidence intervals (CIs) using a random effects model.

A total of 13 studies involving 639 transgender individuals (392 MTF and 247 FTM) were included in the analysis. The body of evidence was obtained mostly from observational studies with a moderate risk of bias.

Compared with baseline values before initiation of masculinizing hormone therapy, 12- and 24-month assessment data showed that FTM individuals had no statistically significant difference in the lumbar spine, femoral neck or total hip bone BMD.

On the other hand, MTF individuals had a statistically significant increase in lumbar spine BMD at 12 months (0.04 g/cm2; 95 percent CI, 0.03 to 0.06 g/cm2) and 24 months (0.06 g/cm2; 0.04 to 0.08 g/cm2) when compared with baseline values before they started using feminizing hormone therapy.

No events were reported at 12 months following the assessment of fracture rates in a single cohort of 53 MTF and 53 FTM individuals.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
2 days ago
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
Tristan Manalac, 6 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
Pearl Toh, 3 days ago
Patients with inflammatory bowel disease (IBD) who had primary nonresponse to an anti-tumour necrosis factor (TNF) agent ─ or inadequate response to the initial loading doses ─ were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.
Tristan Manalac, 16 Feb 2018
Placebo pills, even when administered open-label, appear to significantly improve cancer-related fatigue and fatigue-disrupted quality of life, according to a recent study.